Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719170 · ClinicalTrials.gov registry record · NA
Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program
A NA study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 220,306
- Enrollment target
NCT03719170: Completed NA study, sponsored by VA Office of Research and Development.
NCT03719170 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 220,306 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03719170, a NA study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 220,306 participants
- Enrollment target
Study Summary
Proton pump inhibitors (PPIs) are medications used to treat acid-related stomach disorders, such as chronic heartburn. These medications are widely used by Veterans, with over 11 million 30-day prescriptions being filled each year. Though they are highly effective, long-term use of PPIs may be harmful. For this reason, experts recommend that PPIs be stopped in patients who do not have a clear need for these medications. Unfortunately, PPIs continue to be overused. To address this issue, the VA is implementing a national program to de-prescribe (i.e., reduce the dose of, or stop) PPIs. In this study, the investigators will be evaluating this national program by assessing: (a) how successfully the program was implemented; (b) understanding how effective the program was in improving appropriate use of PPIs; and, (c) ensuring no unintended consequences (such as peptic ulcer bleeding) occurred with PPI de-prescribing. This study addresses a potential safety concern for Veterans and aligns with VA's broader goal of de-implementing low-value care.
Interventions
- BEHAVIORAL PPI De-prescribing Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220,306 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2021-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03719170
The ClinicalTrials.gov registry entry for NCT03719170 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 220,306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PPI De-prescribing Program is the first listed.
NCT03719170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03719170 about?
NCT03719170 is a clinical study titled "Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program". Proton pump inhibitors (PPIs) are medications used to treat acid-related stomach disorders, such as chronic heartburn. These medications are widely used by Veterans, with over 11 million 30-day prescriptions being filled each year. Though they are highly effective, long-term use of PPIs may be harmf...
What is the current status of trial NCT03719170?
This trial is currently completed. It is a NA study. The enrollment target is 220,306 participants. The study started on 2019-09-16. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT03719170?
The interventions under investigation include: PPI De-prescribing Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT03719170?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.